Skin closure systems and devices of improved flexibility and stretchability for bendable joints

Information

  • Patent Grant
  • 11883264
  • Patent Number
    11,883,264
  • Date Filed
    Thursday, October 10, 2019
    5 years ago
  • Date Issued
    Tuesday, January 30, 2024
    9 months ago
Abstract
A system or device for skin closure comprises an elastic flat flexible tape elongated along a longitudinal axis and having a lower side and an opposing upper side, said tape having a pressure sensitive adhesive on at least a portion of the lower side, said tape having a plurality of openings arranged side-by-side with spaces between said openings oriented across the longitudinal axis.
Description

The present disclosure relates to skin closure systems and devices comprising elastic flat flexible tape elongated along a main axis and having a lower side and an opposing upper side, said tape having a pressure sensitive adhesive on at least a portion of the lower side, said tape having a plurality of openings arranged side-by-side with spaces between said openings oriented across the main axis. Skin closure device is applied over a surgical incision and secured by polymerizable adhesive.


BACKGROUND

A number of devices and methods exist for closing skin or tissue having a surgical opening, cut, wound, or dissection, whereby skin or tissue parts separated by the cut are approximated or brought into close proximity forming as narrow gap as possible in the area of the surgical dissection or cut, and then covered by an adhesively attached tape which holds the skin or tissue in closed apposed arrangement until wound healing whereby the tape is removed.


Commercially available DERMABOND® PRINEO® Skin Closure System comprises a mesh having a pressure sensitive adhesive and a polymerization initiator disposed on the mesh. The mesh is applied onto the skin over a wound, and a polymerizable cyanoacrylate based adhesive is then applied on the mesh and bonds the mesh to the skin. However, skin closure systems, such as DERMABOND® PRINEO® Skin Closure System, may benefit from more stretching for flexibility/joint articulation if applied over a joint, such as knee, elbow, or similar, while holding the dissection applied lengthwise or longitudinally along the joint.


A number of attempts to address this issue are known, including commercial products: such as TopClosure® 3S System—Skin Stretching and Secure Wound Closure System; Steri-Strip™ by 3M™; Zip®16 Surgical Skin Closure by Zipline Medical. These known systems are complex and either lack flexibility or lack secure and lasting bonding and coverage which extends for the time needed for full healing, such as 1-2 weeks.


PCT publication No. WO2008/082444 titled “Articles and Methods for Tissue Repair” discloses a method of medically treating a tissue comprising: directing a transfer device to a tissue surface, the transfer device having associated therewith a patterned array of an adhesive; transferring at least a portion of the patterned array of adhesive from the transfer device to the tissue surface by contact adhesion; moving the transfer device away from the tissue surface; positioning an article to be adhered adjacent at least a portion of the adhesive; and adhering the article to the tissue surface using the adhesive.


U.S. Pat. No. 8,353,966 entitled “Scaffold for Bone and Tissue Repair in Mammals” discloses a tissue scaffold for repair and regeneration of bone hard tissue or muscle, skin, or organ soft tissue, the scaffold comprising: a rigid scaffold body having a scaffold central axis, a scaffold transverse dimension, and a scaffold lengthwise dimension which is greater than the scaffold transverse dimension, the scaffold body having a compressive strength between about 20 and about 250 MPa and comprising: biocompatible inorganic glass fibers each having a fiber transverse dimension and a fiber lengthwise dimension which is at least about 10 times the fiber transverse dimension; and an interconnected porosity constituting between about 10 vol. % and about 35 vol. % of the scaffold body; wherein each of the fibers has a diameter between about 20 and about 5000 microns; wherein at least about 75 vol. % of the fibers are longitudinally co-aligned and lie generally lengthwise of the scaffold central axis, are generally free of helical orientation about the scaffold central axis, and are arranged to define open channels within the scaffold which allow fluid flow into and lengthwise within the scaffold; and wherein the fibers are self-bonded together in that adjacent longitudinally aligned fibers are fused together.


U.S. Pat. No. 6,652,559 entitled “Wound Closure System” discloses a wound closure system for closing a wound on a patient, comprising: an elongated flexible backing strip having opposite ends, first and second surfaces facing away from one another and a length and width sufficient to secure facing edges of the wound in close juxtaposition to one another, said backing strip comprising a first portion disposed between said ends and adapted to overlie the facing edges of said wound, and second and third portions disposed on either side of said first portion and each provided with a predetermined number of spaced-apart perforations extending through said backing strip from said first surface to said second surface, said first portion being free of any aperture extending through said backing strip from said first surface to said second surface; a first pressure-sensitive adhesive coated on at least part of the first surface of said backing strip including said second and third portions thereof, to adhere at least said second and third portions of said backing strip to the patient with the facing edges of said wound in said close juxtaposition; a first protective member removably attached to said backing strip and covering said pressure-sensitive adhesive; and a flowable, moisture-curable surgical adhesive for application into said perforations to strengthen the adhesion of said second and third portions of said backing strip to the patient; whereby after (a) removal of said protective member to expose said pressure-sensitive adhesive, (b) application of said backing strip with the exposed pressure-sensitive adhesive onto said patient to secure the facing edges of said wound in said close juxtaposition, and (c) application of said surgical adhesive into said apertures, said surgical adhesive flows through said perforations and upon curing forms discrete bonding sites cooperating with said backing strip to maintain the facing edges of said wound in said close juxtaposition without the cured adhesive adversely affecting the flexibility of said backing strip, wherein a second protective member having a second pressure-sensitive adhesive coated on one side thereof is removably attached to said backing strip and covers said second surface, said strip being disposed between said first and second protective members, and wherein said second protective member is provided with a corresponding number of perforations registering with the perforations defined in said second and third portions of said backing strip, and being in flow communication therewith.


U.S. Pat. No. 6,559,350 entitled “MOISTURE-CURABLE ADHESIVE SUTURE STRIP” discloses a moisture-curable adhesive suture strip for closing a wound on a patient, comprising: an elongated, flexible air-permeable backing member formed of a chemically inert material, and having opposite ends, first and second surfaces facing away from one another and a length and width adapted to secure facing edges of the wound in close juxtaposition to one another, said backing member comprising a first portion disposed between said ends and adapted to overlie the facing edges of said wound, and second and third portions disposed on either side of said first portion; a moisture-curable surgical adhesive on at least part of the first surface of said backing member including said second and third portions thereof, in spaced-apart discrete areas of said first surface; a pressure-sensitive adhesive on the first surface of said backing member between said discrete areas for adhering at least said second and third portions of said backing member to the patient with the facing edges of said wound in said close juxtaposition; and a first removable protective member formed of a chemically inert material releasably secured to said backing member and covering said surgical adhesive and said pressure-sensitive adhesive; whereby after removal of said protective member to expose said surgical adhesive and said pressure sensitive adhesive, and application of said backing member with the exposed surgical adhesive pressure sensitive adhesive onto said patient to secure the facing edges of said wound in said close juxtaposition, said surgical adhesive upon curing forms discrete bonding sites strengthening the adhesion of at least said second and third portions of said backing member to the patient and cooperating with said backing member to maintain the facing edges of said wound in said close juxtaposition without the cured adhesive adversely affecting the flexibility of said backing member.


U.S. Patent Application Publication No. 2013/0012988 entitled “Wound Closure Material” discloses wound closure material with a core of biodegradable material, wherein at least one side of the core of biodegradable material is provided with a multitude of discrete spots of an adhesive and the core of biodegradable material comprises an open cell structure.


U.S. Pat. No. 8,642,831 entitled “Device for Promotion of Hemostasis and/or Wound Healing” discloses a hemostatic matrix material comprising a surface and a plurality of open and interconnected cells, said matrix material comprising gelatine or collagen, wherein the surface of said matrix comprises at least one pharmaceutical composition printed onto said surface in individual and discrete locations, wherein said pharmaceutical composition comprises one or more hemostatic agents.


U.S. Patent Application publication No. 2014/0155916 entitled “Multi-layer Porous Film Material” discloses a surgical implant, comprising: a first porous film layer including a plurality of pores; and a second porous film layer including a plurality of pores, the first and second porous film layers being in a stacked configuration and interconnected to one another at a plurality of attachment points to define at least one void between the first and second porous film layers.


U.S. Patent Application publication No. 2008/0109034 entitled “Controlled Adhesive Locations Facilitating Tissue Remodeling” discloses a surgical implant for adhering two portions of tissue together comprising; a) an implantable matrix having at least one layer and a plurality of openings formed within the at least one layer for tissue growth therethrough; and b) a polymer adhesive about the implantable matrix for adhering the two portions of tissue together, the adhesive polymerizing to adhere the tissue together when the two portions of tissue are brought together.


U.S. Patent Application publication No. 2006/0141012 entitled “Tissue Scaffold” discloses a tissue scaffold comprising: a first film including a plurality of cell openings; and a second film adjacent the first film and including a plurality of cell openings larger than the cell openings of the first film; wherein the cell openings of the first film interconnect with the cell openings of the second film to define pathways extending from the first film to the second film.


U.S. Patent Application publication No. 2013/0204077 entitled “Surgical Scaffolds” discloses a surgical scaffold for soft tissue repair, said surgical scaffold comprising a sheet of non-filamentous polymeric material, at least a portion of the sheet surface comprising a plurality of through-holes.


Leukosan® SkinLink by BSN Medical and distributed by Smith and Nephew Pty Ltd, has an apertured band-aid like structure.


Synthetic tissue adhesive TissuGlu® Surgical Adhesive by Cohera Medical, Inc. is based on a polyurethane prepolymer and is applied in a spot-like discrete application of the adhesive during abdominoplasty, using a multi-point dispenser.


Very flexible and elastic tapes will allow for joint flexibility, but will not hold the skin areas in apposed arrangement due to the same elasticity, potentially resulting in wound dehiscence or surgical complication in which a wound ruptures along a surgical incision. Other known systems fail to fully cover the wound resulting in potential for ingress of contaminants and infection causing microorganisms. Other known systems are overly rigid preventing articulation or bending of the joint.


There continues to be a need for improved devices, systems, and methods for holding skin areas around the dissection in apposed arrangement while still providing for flexibility in longitudinal direction enabling bending of the underlying joints.


SUMMARY OF THE INVENTION

In one embodiment, a device for skin closure comprises an elastic flat flexible tape elongated along a main axis and having a lower side and an opposing upper side, said tape having a pressure sensitive adhesive on at least a portion of the lower side, said tape having a plurality of openings arranged side-by-side with spaces between said openings oriented across the main axis.


According to another embodiment, there is provided a method of skin closure, comprising the steps of disposing the device onto skin having a surgical incision with the main axis approximately aligned with the surgical incision; apposing and approximating edges of the incision to each other; using the pressure sensitive adhesive to fixate the device on skin; applying a polymerizable adhesive onto the upper side into the openings; Allowing the polymerizable adhesive to polymerize and bond to skin and to the device; rendering the device substantially not stretchable in the directions perpendicular to the main axis but stretchable along the main axis providing for flexibility and enabling bending of underlying joints; providing coverage of the incision and keeping the incision closed.





BRIEF DESCRIPTION OF THE DRAWINGS


FIGS. 1A-D show applications of an embodiment of the device of the skin closure system to a joint in schematic side and top views.



FIGS. 2A-E show embodiments of the skin closure device in schematic top view and cross-sectional side views.



FIGS. 3A-B show embodiments of the skin closure device in a schematic top view and a cross-sectional side view.



FIGS. 4A-B show an embodiment of the skin closure device in a schematic top view and cross-sectional side view.



FIG. 5 shows an embodiment of the skin closure device in a schematic top view.



FIGS. 6A-C show embodiments of the skin closure device in schematic top views.



FIGS. 7A-B show embodiments of the skin closure device in schematic top views.



FIGS. 8A-C show embodiments of the skin closure device in schematic top views.



FIGS. 9A-B show embodiments of the skin closure device in schematic top views.



FIGS. 10A-B show embodiments of the skin closure device in schematic top views.



FIGS. 11A-B show embodiments of the skin closure device in schematic top views.



FIG. 12 shows an embodiment of the skin closure device in a schematic top view.





DETAILED DESCRIPTION

Referring now to FIG. 1, a schematic cross-sectional view of a joint 100, such as knee or elbow (knee is shown), with an embodiment of device 10 applied over the joint 100, which is not bent, as seen in FIG. 1A, or bent as shown in FIG. 1B. FIG. 1C shows joint 100 in top view, with the surgical incision or wound 110 present and directed along the limb having joint 100. FIG. 1D shows joint 100 in top view, with an embodiment of device 10 of the present invention applied to joint 100 and fully covering surgical incision or wound 110. Device 10 is elongated and applied along the limb having joint 100 and along surgical incision or wound 110.


Referring now to FIG. 2, embodiments of Skin Closure System device 10 are shown, with device 10 comprising a thin, flat, flexible and elastic tape 20 having length L and width W and elongated along axis 21, with upper side 22 and lower side 23, with tape 20 having a plurality of openings 30 each spanning a large portion of the width W of tape 20 or the whole width W (as shown, e.g., in FIG. 3), with openings 30 arranged side by side along the length L and separated by spacer areas 35. Openings 30 are fully covered by porous mesh 40 preferably having an initiator or accelerator of polymerization disposed on the mesh 40, coated on the mesh 40, and/or impregnated into the mesh 40. Preferably, initiator or accelerator of polymerization is disposed, coated, or impregnated onto/into at least openings 30 or mesh present in opening 30, or onto whole tape 20.



FIG. 2A shows the top view of device 10 while FIGS. 2B, 2C, 2D show cross-sectional views of different constructions corresponding to top view 2A. According to an embodiment of device 10 shown in FIG. 2B, mesh 40 has the thickness similar to thickness T of tape 20, with mesh present within openings 30. As used herein, the term “present” means that the mesh is exposed or disposed or positioned within openings 30. According to an embodiment of device 10 shown in FIG. 2C, mesh 40 has thickness which is lower than thickness T of tape 20, with mesh present within openings 30. According to an embodiment of device 10 shown in FIG. 2D, mesh 40 is disposed on a lower surface of tape 20.


Mesh 40 alternatively can be a porous nonwoven, felt, porous woven fabric, textile, foam, or similar. Mesh 40 can also be an extruded film porated during or after extrusion or formed directly with apertures.


Tape 20 is made of a polymeric flexible and elastic material. Elastic property is defined by stretchability at least in the lengthwise direction, with stretchability from 1% to 50% of length when exposed to 1 N of force, more preferably 3%-25% of the initial or unstressed length. The ‘elastic’ property is a function of the material from which the mesh is constructed and/or the nature of the mesh construction itself. Mesh 40 is made of flexible material, which can optionally also be elastic. Mesh 40 can be polymeric, metal, ceramic, natural fiber, etc., with preferable material being polymeric. Lower side 23 has optionally a pressure sensitive adhesive (PSA) disposed thereon, which can cover the whole lower side 23, or only a portion of lower side 23 in any pattern. In one embodiment, PSA is applied in equally spaced stripes across whole lower side 23. In another embodiment, PSA is applied only on the areas free of openings 30 on lower side 23. In another embodiment, PSA is applied only on the areas where openings 30 are present on lower side 23 and optionally above and below openings 30. In yet another embodiment, PSA is applied uniformly everywhere on lower side 23. FIG. 2E shows PSA 45 disposed on tissue facing or wound facing lower side 23. PSA can be on tape 20 and/or on mesh 40.


In use and referring to FIG. 2, device 10 is disposed on tissue or skin having a wound with axis 21 approximately aligned with the surgical incision or wound, with the edges of the incision apposed and approximated to each other. A polymerizable adhesive is then applied onto upper side 22, onto the whole upper side 22 surface or more preferably only onto/into openings 30 on upper side 22. If an initiator or accelerator is present, the polymerizable adhesive reacts with the initiator or accelerator of polymerization disposed on the mesh 40, coated on the mesh 40, and/or impregnated into the mesh 40 resulting in polymerization and bonding of the adhesive to the skin or tissue in the areas corresponding to openings 30 and to the device 10. Bonding to device 10 is at least in part due to bonding to mesh 40 disposed within openings 30.


The application of adhesive results in device 10 being bonded to the skin and covering the wound or incision while holding skin areas around the dissection in apposed arrangement. Due to presence of the adhesive, device 10 is substantially not stretchable in the directions perpendicular to axis 21, keeping the wound or incision closed and skin areas around the dissection in apposed arrangement. At the same time device 10 is stretchable along the main axis providing for flexibility in longitudinal direction enabling bending of the underlying joints, while also providing coverage of the wound or incision. Advantageously, wound dehiscence or surgical complication in which a wound ruptures along a surgical incision is therefore prevented, while also fully covering the wound and enabling articulation or bending of the joint.


Referring now to FIGS. 3A and 3B, embodiments of Skin Closure System device 10 similar to the embodiments of FIG. 2 are shown, with plurality of openings 30 each spanning the whole width of tape 20, with openings 30 arranged side by side along the length of tape 20 and separated by spacer areas 35. According to an embodiment of device 10 shown in FIG. 3B showing a cross-sectional view, mesh 40 is disposed on a lower surface of tape 20.


According to an embodiment (not shown), there is provided a kit, comprising device 10, a container containing a polymerizable or cross-linkable liquid adhesive, and a dispenser adapted to dispense adhesive. In one embodiment, dispenser has a tip for expressing the polymerizable adhesive, wherein the tip has a width equal to a width of openings 30.


Referring now to FIGS. 4A and 4B, embodiments of Skin Closure System device 10 similar to the embodiments of FIGS. 2,3 are shown, but with openings 30 comprising areas of porated or perforated tape 20, with no mesh 40 used to form device 10 of this embodiment. Preferably, initiator or accelerator of polymerization is disposed, coated, or impregnated onto/into at least openings 30 comprising areas of porated or perforated tape 20 or onto whole tape 20.


No Mesh


Referring now to FIG. 5, an embodiment of Skin Closure System device 10 similar to the embodiments of FIGS. 2, 4 are shown, but with openings 30 comprising areas of material removed from tape 20, with no pores or mesh within openings 30, i.e., openings 30 comprising cut-outs or holes with no material disposed within openings 30. In use, this embodiment is preferably utilized with an adhesive dispenser which has initiator or accelerator of polymerization admixed into the adhesive upon dispensing, such as from a porous tip impregnated with initiator or accelerator of polymerization.


In use and referring to FIG. 5, device 10 is disposed on tissue or skin having a wound with axis 21 approximately aligned with the surgical incision or wound, with the edges of the incision apposed and approximated to each other. A polymerizable adhesive is then applied onto upper side 22 onto the whole upper side 22 surface or more preferably only onto/into openings 30 on upper side 22. The polymerizable adhesive is dispensed from a porous tip impregnated with initiator or accelerator of polymerization, reacts with the initiator or accelerator of polymerization, if present, resulting in polymerization and bonding of the adhesive to the skin or tissue in the areas corresponding to openings 30 and to the device 10. The application of adhesive results in device 10 being bonded to the skin or tissue in the areas corresponding to openings 30 and covering the wound or incision while holding skin areas around the dissection in apposed arrangement. Due to presence of the adhesive, device 10 is substantially not stretchable in the directions perpendicular to axis 21, keeping the wound or incision closed and skin areas around the dissection in apposed arrangement. At the same time device 10 is stretchable along the main axis providing for flexibility in longitudinal direction enabling bending of the underlying joints.


Mask


Referring now to FIG. 6, an embodiment of Skin Closure System device 10 similar to the embodiments of FIGS. 2A, 2D is shown. FIG. 6A shows assembled device 10 which comprises tape 20a shown in FIG. 6B, representing a removable mask 20a which is made of a polymeric flexible material which can be optionally non-elastic or elastic, with mask 20a releasably disposed on mesh 40a shown in FIG. 6C, with mesh 40a made of polymeric flexible and elastic material. Mask 20a is attached to mesh 40 with a weak PSA disposed on mask 20a (not shown) or by a compression fit or by any other method known in the art assuring easy release of mask 20a from mesh 40a. Optional one or more tabs 25 are provided for easy lift-off and removal of mask 20a. In an alternative embodiment (not shown) mask 20a is larger than mesh 40a and the edges of mask 20a can be used as tabs 25.


In operation, assembled device 10 is disposed on tissue or skin having a wound with axis 21 approximately aligned with the surgical incision or wound, with the edges of the incision apposed and approximated to each other. A polymerizable adhesive is then applied onto upper side 22, onto the whole upper side 22 surface or more preferably only onto/into openings 30 on upper side 22. Mask 20a is then removed and discarded. All of the excess adhesive is removed on mask 20a. The polymerizable adhesive reacts with the initiator or accelerator of polymerization if disposed on the mesh 40, if coated on the mesh 40, and/or if impregnated into the mesh 40 resulting in polymerization and bonding of the adhesive to the skin or tissue and to mesh 40 in the areas of mesh 40 corresponding to openings 30. The application of adhesive results in mesh 40 being bonded to the skin and covering the wound or incision while holding skin areas around the dissection in apposed arrangement. Due to presence of the adhesive, mesh 40 is substantially not stretchable in the directions perpendicular to axis 21, keeping the wound or incision closed and skin areas around the dissection in apposed arrangement. At the same time device 10 is stretchable along the main axis providing for flexibility in longitudinal direction enabling bending of the underlying joints.


Referring now to FIG. 7, an embodiment of Skin Closure System device is shown which is a combination of the device 10 of embodiments of FIG. 2A or 4 (shown in FIG. 7A) with mask 20a (shown in FIG. 7B) of embodiment of FIG. 6 is shown. Skin Closure System device, in this embodiment, comprises a combination of device 10 of embodiment 2A or 4 comprising tape 20 having a plurality of openings 30 as shown in FIG. 7A with removable mask 20a which is shown in FIG. 7B having openings 30a which have substantially similar dimensions and positions and are in registration with openings 30 on device 10. Mask 20a is then releasably disposed on device 10 upper side 22 and can be attached with a weak PSA disposed on mask 20a or by a compression fit or by any other method known in the art assuring easy release of mask 20a, with openings 30a in registration with openings 30. Optionally, one or more tabs 25 are provided for easy lift-off and removal of mask 20a. In an alternative embodiment (not shown) mask 20a is larger than mesh 40a and the edges of mask 20a can be used as tabs 25.


In operation, assembled Skin Closure System device with device 10 with mask 20a disposed on upper side 22 is disposed on tissue or skin having a wound with axis 21 approximately aligned with the surgical incision or wound, with the edges of the incision apposed and approximated to each other. A polymerizable adhesive is then applied onto mask 20a surface or more preferably only onto/into openings 30 and 30a. Mask 20a is then removed and discarded. All of the excess adhesive is removed on mask 20a. The polymerizable adhesive reacts with the initiator or accelerator of polymerization if disposed on the mesh 40, if coated on the mesh 40, and/or if impregnated into the mesh 40 resulting in polymerization and bonding of the adhesive to the skin or tissue and to mesh 40 in the areas of mesh 40 corresponding to openings 30. The application of adhesive results in mesh 40 being bonded to the skin and covering the wound or incision while holding skin areas around the dissection in apposed arrangement. Due to presence of the adhesive, mesh 40 is substantially not stretchable in the directions perpendicular to axis 21, keeping the wound or incision closed and skin areas around the dissection in apposed arrangement. At the same time device 10 is stretchable along the main axis providing for flexibility in longitudinal direction enabling bending of the underlying joints.


Separate Openings


Referring now to FIG. 8, an embodiment of Skin Closure System device 10 is shown, with device 10 comprising a thin, flat, flexible and elastic tape 20 elongated along axis 21, with tape 20 having a plurality of openings 30b arranged side by side along the length L and separated by longitudinal spacer areas 35 and further arranged above and below axis 21 and separated by axial spacer areas 36, with no openings 30b overlapping axis 21. As shown in FIG. 8A, in one embodiment, openings 30b are fully covered by porous mesh 40 with mesh 40 preferably having an initiator or accelerator of polymerization disposed on the mesh 40, coated on the mesh 40, and/or impregnated into the mesh 40. In an alternative embodiment shown in FIG. 8B, openings 30b have no mesh disposed within the openings, i.e. openings 30b are comprising cut-outs or holes with no material disposed within openings 30b. Tape 20 is made of a polymeric flexible and elastic material. Mesh 40 is made of polymeric flexible material, which can optionally also be elastic. Lower side 23 has optionally a pressure sensitive adhesive (PSA) disposed thereon, which can cover the whole lower side 23, or only a portion of lower side 23 in any pattern.


In use, device 10 is disposed on tissue or skin having a wound with axis 21 approximately aligned with the surgical incision or wound, with the edges of the incision apposed and approximated to each other. A polymerizable adhesive 50 is then applied onto upper side 22, or more preferably only onto/into openings 30b on upper side 22 and onto axial spacer areas 36 formed between openings 30b opposing each other across axis 21, as shown in FIG. 8C. The polymerizable adhesive polymerizes resulting in bonding of adhesive 50 to the skin or tissue and to the device 10. Simultaneously, a portion of adhesive 50a coated on upper side 22 between openings 30b axial spacer areas 36 forms areas of lesser stretchability and higher rigidity 36b between openings 30b opposing each other across axis 21, as shown by hatched line shadowing in FIG. 8C. Portions of adhesive 50 and 50a can polymerize due to initiator if disposed on mesh 40, and/or on upper side of tape 20, and/or on upper side of tape 20 in axial spacer areas 36 between openings 30b. With regards to the embodiment shown in FIG. 8B, whereby openings 30b have no mesh disposed within the openings, the polymerizable adhesive can be dispensed from a porous tip impregnated with initiator or accelerator of polymerization, whereby adhesive reacts with the initiator or accelerator of polymerization, resulting in polymerization and bonding of the adhesive to the skin or tissue and to the device 10.


The application of adhesive results in device 10 being bonded to the skin and covering the wound or incision while holding skin areas around the dissection in an apposed arrangement and thereby forming a composite of the device with the polymerized adhesive. Due to presence of the adhesive, device 10 is substantially not stretchable in the directions perpendicular to axis 21, keeping the wound or incision closed and skin areas around the dissection in apposed arrangement. At the same time device 10 is stretchable along the main axis providing for flexibility in longitudinal direction enabling bending of the underlying joints, while also providing coverage of the wound or incision. Advantageously, in the embodiments of FIG. 8, no adhesive is in direct contact with the surgical cut or wound area, which area is positioned substantially aligned with axis 21 and under axial spacer areas 36 between openings 30b, resulting in no contact of adhesive with cut tissue.


Variable Width


Referring now to FIG. 9A, an embodiment of Skin Closure System device 10 is shown, with openings 30 separated by spacers of varying width, whereby in the middle M of device 10 spacer areas 35a are wider and towards the ends spacer areas 35b are narrower, and close to the ends spacer areas 35c are narrowest. This results in more stretchability around the center or middle M of device 10 as stretchability is defined by spacer areas 35. Optionally, openings 30 become wider further from the center of middle M and close to the ends of device 10, as shown by openings 31 which are about 2-3 times wider than openings 30 which are closer to the middle. This results in more stretchability around the center or middle M of device 10.


Referring now to FIG. 9B, an embodiment of Skin Closure System device 10 is shown, with openings in tape 20 having variable width, with openings 32a narrowest in the middle M of device 10, openings 32b, 32c wider towards the ends of the devices, and with openings 32e close to the end of the device 10 being widest, such as 2-10 times wider vs. openings 32a. This results in more stretchability around the center or middle M of device 10. Spacer areas 35 can be of uniform width, as shown, or of varying width (not shown) similar to presented in FIG. 9A.


Slits


Referring now to FIG. 10, embodiments of Skin Closure System device 10 are shown, with slits 60 cut into periphery of tape 20. Slits 60 can be of any shape, such as rectangular cuts 60a or triangular cuts 60b. Slits 60 can be cut into periphery of tape 20 in the areas between openings 20, as shown in FIG. 10A, or be aligned with openings 30, as shown in FIG. 10B. Slits 60 penetrate tape 20 for about 3% to about 20% of the width W of tape 20, but in no case slits 60 penetrate into openings 30. Slits 60 provide for more stretchability of device 10. Slits 60 also allow for some lateral bending of device 10 for non-linear incisions. In some embodiments (not shown) slits 60 are only present around center or middle M of tape 20. Slits 60 can also be just on one side of device 10.


Shapes


In one embodiment, the width W of the device varies along the axis 21. In one embodiment, width W is more narrow in the central region M than at the ends. In another embodiment, width W is wider in the central region M than at the ends.


Referring now to FIG. 11A, an embodiment of Skin Closure System device 10 is shown, with openings 30 having concave rectangle or bow-tie shape having narrower width closer to axis 21 and wider width further from axis 21. Spacer areas 35 have elliptical or rhombus shape or similar, being wider closer to axis 21 and narrower further from axis 21.


Referring now to FIG. 11B, an embodiment of Skin Closure System device 10 is shown, with openings 30 having elliptical or rhombus shape or similar, having wider width closer to axis 21 and narrower width further from axis 21. Spacer areas 35 have bow-tie shape or similar, being narrower closer to axis 21 and wider further from axis 21. Optimization of shape of openings 30 and/or spacer areas 35 results in more stretchability around the center or middle M of device 10.


Referring now to FIG. 12, an embodiment of Skin Closure System device is shown, with tape 20 represented by elliptical non-connected islands 20b of little or no porosity. Islands 20b can be of varying width. Openings 30 are of bow-tie shape and are formed between islands 20b of mesh 40.


In one embodiment, there are narrow cuts (not shown) in spacer areas 35 separating openings 30, the cuts comprising narrow slits in tape 20 oriented perpendicular to axis 21 and having length not more than 80% of width W, such as 25, 50%. The cuts can be only between some openings 30 or between all openings 30.


Sizes


Tape 20 can be of any elongated shape to cover an articulating joint, such as elliptical, rectangular, and similar. Tape 20 can have ratio of length to width of about 1:2 to about 1:20, such as 1:5. The length of tape 20 is from about 10 cm to about 50 cm, such as 25 cm. The width of tape 20 is from 2 cm to 10 cm, such 3 cm, 5 cm.


Openings 30 can be rectangular, elliptical, circular, etc., and occupy from 30% to 80% of tape 20 area. Width W′ of openings 30 is from 2 mm to 12 mm, more preferable 3 mm to 10 mm. The longitudinal dimension or length L′ of the openings across the width of the tape W is configured so that openings occupy at least 60% of the tape width W, preferably 60 to 100%, more preferably 70-90% of W. Width W′ of openings 30 is configured to be at least 5% of L′, preferably 5%-100% of L′, more preferably at 20-30% of L′.


Porosity of mesh 40 or tape 20 porated areas in openings 30 is defined by size of pores or holes being from about 0.01 mm2 to about 4 mm2, more preferably 0.1 mm2 to 1 mm2. Percent of open area in mesh 40, or ratio of area of holes to area of material surrounding holes within openings 30 is from about 95%-about 20%, more preferably 90%-40% constituting open area.


PSA


Optional pressure sensitive adhesive bands or stripes are disposed over lower surface 23, (such as shown in FIG. 2) covering from 10% to 90% of lower surface 23. Other shapes and forms of applying pressure sensitive adhesive are contemplated, including dots, squares, mixed angular bands, etc.


Initiator


In a preferred embodiment, initiators and/or accelerators or rate modifiers of adhesive polymerization or cross-linking can be releasably disposed on mesh 40 or releasably incorporated into mesh 40. For example, one or more chemical substances may be dispersed in or on mesh 40 such as being chemically bound, physically bound, coated, absorbed, or adsorbed to it.


For example, a polymerization initiator or accelerator or rate modifier may be loaded in or on mesh 40 so that the initiator or rate modifier provides the desired initiation or rate modification effect to a subsequently applied polymerizable adhesive composition. The polymerization initiator or rate modifier may be immobilized in or on mesh 40, so that the initiator or rate modifier does not become detached from mesh 40 and its residues are dispersed in the resultant polymeric material. Alternatively, for example, the polymerization initiator or rate modifier may be initially attached to mesh 40, but only in such a manner that it becomes mobilized or solubilized by a subsequently applied polymerizable adhesive composition and dispersed in the resultant polymeric material.


If desired, a combination of chemical substances may also be provided in or on mesh 40, to provide multiple effects. For example, a first chemical species (such as a polymerization initiator or rate modifier) may be immobilized in or on mesh 40, while a second, different chemical species (such as a bioactive material) may be detachably attached to mesh 40. Other combinations of chemical species and resultant effects are also envisioned.


When present in or on mesh 40, the chemical substances (i.e., polymerization initiator, rate modifier, and/or bioactive materials, or other additives), may be incorporated in or on mesh 40 in any suitable manner. For example, the chemical substance may be added to mesh 40 by contacting mesh 40 with a solution, mixture, or the like including the chemical substances. The chemical substance may be added to mesh 40, for example, by dipping, spraying, roll coating, gravure coating, brushing, vapor deposition, or the like. Alternatively, the chemical substance may be incorporated into or onto mesh 40 during manufacture of mesh 40, such as during molding.


The polymerization initiator or rate modifier loaded in or on mesh 40 may provide a number of advantages for example, so as to provide faster polymerization time. The concentration of polymerization initiator or rate modifier may be increased to provide even faster polymerization time.


Because the polymerization initiator or rate modifier is loaded directly in or on mesh 40, it is not necessary to mix the polymerizable adhesive composition with a polymerization initiator or rate modifier prior to application. This may allow a longer working time, where the polymerizable monomer composition may be more precisely and carefully applied over a longer period of time.


Such suitable initiators are known in the art and are described, for example, in U.S. Pat. Nos. 5,928,611 and 6,620,846, both incorporated herein by reference in their entireties, and U.S. Patent Application No. 2002/0037310, also incorporated herein by reference in its entirety. Quaternary ammonium chloride and bromide salts useful as polymerization initiators are particularly suitable. By way of example, quaternary ammonium salts such as domiphen bromide, butyrylcholine chloride, benzalkonium bromide, acetyl choline chloride, among others, may be used.


Benzalkonium or benzyltrialkyl ammonium halides such as benzyltrialkyl ammonium chloride may be used. When used, the benzalkonium halide may be benzalkonium halide in its unpurified state, which comprises a mixture of varying chain-length compounds, or it can be any suitable purified compound including those having a chain length of from about 12 to about 18 carbon atoms, including but not limited to C12, C13, C14, C15, C16, C17, and C18 compounds. By way of example, the initiator may be a quaternary ammonium chloride salt such as benzyltrialkyl ammonium chloride (BTAC).


Other initiators or accelerators may also be selected by one of ordinary skill in the art without undue experimentation. Such suitable initiators or accelerators may include, but are not limited to, detergent compositions; surfactants: e.g., nonionic surfactants such as polysorbate 20 (e.g., Tween 20™ from ICI Americas), polysorbate 80 (e.g., Tween 80™ from ICI Americas) and poloxamers, cationic surfactants such as tetrabutylammonium bromide, anionic surfactants such as sodium tetradecyl sulfate, and amphoteric or zwitterionic surfactants such as dodecyldimethyl(3-sulfopropyl)ammonium hydroxide, inner salt; amines, imines and amides, such as imidazole, arginine and povidine; phosphines, phosphites and phosphonium salts, such as triphenylphosphine and triethyl phosphite; alcohols such as ethylene glycol, methyl gallate; tannins; inorganic bases and salts, such as sodium bisulfate, calcium sulfate and sodium silicate; sulfur compounds such as thiourea and polysulfides; polymeric cyclic ethers such as monensin, nonactin, crown ethers, calixarenes and polymeric-epoxides; cyclic and acyclic carbonates, such as diethyl carbonate; phase transfer catalysts such as Aliquat 336; organometallics such as cobalt naphthenate and manganese acetylacetonate; and radical initiators or accelerators and radicals, such as di-t-butyl peroxide and azobisisobutyronitrile.


Mixtures of two or more, such as three, four, or more, initiators or accelerators may be used. A combination of multiple initiators or accelerators may be beneficial, for example, to tailor the initiator of the polymerizable monomer species. For example, where a blend of monomers is used, a blend of initiators may provide superior results to a single initiator. For example, the blend of initiators can provide one initiator that preferentially initiates one monomer, and a second initiator that preferentially initiates the other monomer, or can provide initiation rates to help ensure that both monomer species are initiated at equivalent, or desired non-equivalent, rates. In this manner, a blend of initiators can help minimize the amount of initiator necessary. Furthermore, a blend of initiators may enhance the polymerization reaction kinetics.


Adhesive


In one embodiment, liquid or semi-liquid adhesive 50 is polymerized or is cross-linking polymerized or is cross-linking after coming in contact with initiators and/or accelerators of adhesive polymerization and/or cross-linking.


Such initiators and/or accelerators can be coated or disposed non-releasably, i.e. immobilized in or on the mesh 40 while retaining activity to initiate or accelerate polymerization and/or cross-linking. In one embodiment, initiators and/or accelerators are disposed releasably, i.e. they can be at least partially released into and mix with flowing adhesive 50.


In a preferred embodiment, adhesive 50 is polymerized or is cross-linking after coming in contact with initiators and/or accelerators releasably disposed in or on the mesh 40. Rapid polymerization and/or crosslinking of adhesive 50 results in bonding of device 10 to tissue.


Adhesive 50 can be any type of biocompatible and rapidly cross-linkable and/or polymerizable compound or mixture of compounds. Rapidly cross-linkable and/or polymerizable means that after initiators or accelerators are added, or after the adhesive is formed from two or more components, it is capable of curing, i.e. cross-linking and/or polymerizing within 0.2 min to about 20 min, more preferably within 0.5 min to 10 min, such as 1, 2, 3, 5 min.


In one embodiment, adhesive 50 is formed prior to application onto mesh 40, for instance by mixing two components contained in separate barrels or a two-barrel syringe, by passing these two components through a mixing tip. In this embodiment, there is no crosslinking initiator or accelerator disposed inside of mesh 40. In one embodiment, adhesive 50 is formed by mixing fibrinogen and thrombin together.


In one embodiment, adhesive 50 comprises fibrinogen, and crosslinking initiator or accelerator disposed inside of mesh 40 comprises thrombin.


In a preferred embodiment, the polymerizable adhesive composition may comprise a polymerizable monomeric adhesive. In embodiments, the polymerizable adhesive composition comprises a polymerizable 1,1-disubstituted ethylene monomer formulation. In embodiments, the polymerizable adhesive composition comprises a cyanoacrylate formulation. In embodiments, synthetic polymerizable adhesive materials such as polyurethane, polyethylene glycol, acrylates, glutaraldehyde and biologically based adhesives may be used.


Suitable .alpha.-cyanoacrylate monomers which may be used, alone or in combination, include alkyl .alpha.-cyanoacrylates such as 2-octyl cyanoacrylate; dodecyl cyanoacrylate; 2-ethylhexyl cyanoacrylate; butyl cyanoacrylate such as n-butyl cyanoacrylate; ethyl cyanoacrylate; methyl cyanoacrylate or other .alpha.-cyanoacrylate monomers such as methoxyethyl cyanoacrylate; 2-ethoxyethyl cyanoacrylate; 3-methoxybutyl cyanoacrylate; 2-butoxyethyl cyanoacrylate; 2-isopropoxyethyl cyanoacrylate; and 1-methoxy-2-propyl cyanoacrylate. In embodiments, the monomers are ethyl, n-butyl, or 2-octyl .alpha.-cyanoacrylate. Other cyanoacrylate monomers which may be used include alkyl ester cyanoacrylates, such as those prepared by the Knoevenagel reaction of an alkyl cyanoacetate, or an alkyl ester cyanoacetate, with paraformaldehyde, subsequent thermal cracking of the resultant oligomer and distillation.


Many other adhesive formulations can be used and are known to a skilled artisan. For example, mixtures containing PEG succinimidyl glutarate can be used as a flowable adhesive.


It should be understood that the foregoing disclosure and description of the embodiments of the present invention are illustrative and explanatory thereof and various changes in the size, shape and materials as well as in the description of the preferred embodiment may be made without departing from the spirit of the invention.

Claims
  • 1. A device for skin closure, comprising a) an elastic flat flexible tape elongated along a longitudinal axis and having a lower side and an opposing upper side,b) said tape comprising a mesh substrate;said tape having a pressure sensitive adhesive on at least a portion of the lower side, further comprising:(i) a removable mask releasably disposed on said tape and having substantially same shape as said tape;(ii) said mask having a plurality of openings arranged side-by-side with spaces between said openings oriented across the longitudinal axis such that the mesh substrate is exposed through the plurality of openings, wherein the openings occupy between 30% and 80% of a total area of the mask, and wherein each of the plurality of openings extends from a first area proximate to a first edge of the mask, across the longitudinal axis, and to a second area proximate to a second edge of the mask; and(iii) the mask further having one or more tabs configured for grasping for lift-off and removal of the mask.
  • 2. The device of claim 1, wherein the mask is made of a polymeric flexible material.
  • 3. The device of claim 2, wherein the polymeric flexible material is elastic.
  • 4. The device of claim 2, wherein the polymeric flexible material is non-elastic.
  • 5. The device of claim 1, wherein the mesh substrate is made of a polymeric flexible material that is elastic.
  • 6. The device of claim 1, wherein the mesh substrate is impregnated with an initiator configured to react with a polymerizable adhesive to accelerate polymerization.
  • 7. The device of claim 1, wherein the tape has a first thickness and the mesh substrate has a second thickness less than the first thickness.
  • 8. The device of claim 1, wherein the mesh substrate is one of a porous nonwoven, a felt, a porous woven fabric, a textile, or a foam.
  • 9. A device for skin closure, comprising: a) an flat flexible tape elongated along a central longitudinal axis and having a lower side and an opposing upper side,b) said tape having a pressure sensitive adhesive on at least a portion of the lower side,c) said tape having a plurality of openings arranged side-by-side with spaces between said openings oriented across the central longitudinal axis; andd) said openings further arranged above and below the central longitudinal axis of said tape and separated by axial spacer areas with no openings overlapping said central longitudinal axis, wherein the openings comprise a porous mesh and said axial spacer areas are non-porous, wherein the openings occupy between 30% and 80% of a total area of the tape, wherein a width of the openings is between 2 mm to 12 mm.
  • 10. The device of claim 9, wherein the tape is made of a polymeric flexible material.
  • 11. The device of claim 10, wherein the polymeric flexible material is elastic.
  • 12. The device of claim 10, wherein the polymeric flexible material is non-elastic.
  • 13. The device of claim 9, wherein the porous mesh is made of a polymeric flexible material that is elastic.
  • 14. The device of claim 9, wherein the porous mesh includes an initiator configured to react with a polymerizable adhesive to accelerate polymerization.
  • 15. The device of claim 9, wherein the porous mesh is one of a porous nonwoven, a felt, a porous woven fabric, a textile, or a foam.
US Referenced Citations (351)
Number Name Date Kind
167162 French Aug 1875 A
1656199 Ensley Jan 1928 A
2399545 Davis Apr 1946 A
2508855 Brown May 1950 A
2721858 Joyner et al. Oct 1955 A
2722220 Mestrand Nov 1955 A
2807262 Lew Sep 1957 A
2905174 Smith May 1959 A
3085572 Blackford Apr 1963 A
3254111 Hawkins et al. May 1966 A
3402716 Baxter Sep 1968 A
3520300 Flower, Jr. Jul 1970 A
3731683 Zaffaroni May 1973 A
3888247 Stenvall Jun 1975 A
3940362 Overhults Feb 1976 A
3983878 Kawchitch Oct 1976 A
3995641 Kronenthal et al. Dec 1976 A
4068664 Sharp et al. Jan 1978 A
4080348 Korpman Mar 1978 A
4126130 Cowden et al. Nov 1978 A
4140115 Schonfeld Feb 1979 A
4263906 Finley Apr 1981 A
4313865 Teramoto et al. Feb 1982 A
4340043 Seymour Jul 1982 A
4364876 Kimura et al. Dec 1982 A
4390519 Sawyer Jun 1983 A
4460369 Seymour Jul 1984 A
4560723 Millet et al. Dec 1985 A
4584355 Blizzard et al. Apr 1986 A
4585836 Homan et al. Apr 1986 A
4591622 Blizzard et al. May 1986 A
4612230 Liland et al. Sep 1986 A
4614183 McCracken et al. Sep 1986 A
4630603 Greenway Dec 1986 A
4655767 Woodard et al. Apr 1987 A
4671266 Legnyel et al. Jun 1987 A
4720513 Kameyama et al. Jan 1988 A
4728380 Jones Mar 1988 A
4733659 Edenbaum et al. Mar 1988 A
4767401 Seiderman Aug 1988 A
4793887 Card et al. Dec 1988 A
4793888 Card et al. Dec 1988 A
4795435 Steer et al. Jan 1989 A
4852571 Gadsby et al. Aug 1989 A
4867747 Yarger Sep 1989 A
4872450 Austad Oct 1989 A
4950282 Beisang et al. Aug 1990 A
4966605 Thieler Oct 1990 A
4999235 Lunn et al. Mar 1991 A
5035687 Sandbank Jul 1991 A
5059424 Cartmell et al. Oct 1991 A
5086763 Hathman Feb 1992 A
5088483 Heinecke Feb 1992 A
5106362 Gilman Apr 1992 A
5125907 Philpott Jun 1992 A
5164444 Bernard Nov 1992 A
5173302 Holmblad et al. Dec 1992 A
5232958 Mallya et al. Aug 1993 A
5254132 Barley et al. Oct 1993 A
5259835 Clark et al. Nov 1993 A
5266371 Sugii et al. Nov 1993 A
D347059 Mota May 1994 S
5308313 Karami et al. May 1994 A
5328687 Leung et al. Jul 1994 A
5336209 Porzilli Aug 1994 A
5415626 Goodman et al. May 1995 A
5429592 Jensen Jul 1995 A
5445597 Clark et al. Aug 1995 A
5449340 Tollini Sep 1995 A
D363126 Dusek Oct 1995 S
5456660 Reich et al. Oct 1995 A
5476440 Edenbaum Dec 1995 A
5486547 Matsuda et al. Jan 1996 A
D370258 Newman May 1996 S
D373750 Gunderson Sep 1996 S
5571079 Bello et al. Nov 1996 A
5575997 Leung et al. Nov 1996 A
5582834 Leung et al. Dec 1996 A
5599858 Buchanan et al. Feb 1997 A
5620702 Podell et al. Apr 1997 A
5623011 Bernard Apr 1997 A
5624669 Leung et al. Apr 1997 A
D382343 Wandell et al. Aug 1997 S
5653769 Barley, Jr. et al. Aug 1997 A
D383211 Dunshee et al. Sep 1997 S
5662599 Reich et al. Sep 1997 A
D387169 Dunshee et al. Dec 1997 S
D389244 Dunshee et al. Jan 1998 S
5705551 Sasaki et al. Jan 1998 A
D391639 Dunshee et al. Mar 1998 S
5749895 Sawyer et al. May 1998 A
5762955 Smith Jun 1998 A
5780048 Lee Jul 1998 A
5782788 Widemire Jul 1998 A
5823983 Rosofsky et al. Oct 1998 A
5823986 Peterson Oct 1998 A
D402371 Haynes et al. Dec 1998 S
D403425 Hinds et al. Dec 1998 S
D404139 Young Jan 1999 S
5861348 Kase Jan 1999 A
5876745 Muraoka et al. Mar 1999 A
5902443 Kanakubo et al. May 1999 A
5928611 Leung Jul 1999 A
5931800 Rasmussen et al. Aug 1999 A
5947917 Carté et al. Sep 1999 A
5951505 Gilman et al. Sep 1999 A
5998694 Jensen et al. Dec 1999 A
D424699 Allen May 2000 S
6093465 Gilchrist et al. Jul 2000 A
6125265 Yamamoto et al. Sep 2000 A
6140548 Hansen et al. Oct 2000 A
6143352 Clark et al. Nov 2000 A
6155265 Hammerslag Dec 2000 A
6183593 Narang et al. Feb 2001 B1
D439973 Choksi Apr 2001 S
6217603 Clark et al. Apr 2001 B1
6238692 Smith May 2001 B1
6245960 Eaton Jun 2001 B1
6284941 Cox et al. Sep 2001 B1
6310166 Hickey et al. Oct 2001 B1
6329564 Lebner Dec 2001 B1
6352704 Nicholson et al. Mar 2002 B1
D458687 Dale et al. Jun 2002 S
6410818 Oyaski Jun 2002 B1
6439789 Balance et al. Aug 2002 B1
D463564 Siegwart et al. Sep 2002 S
6455064 Narang et al. Sep 2002 B1
6479725 Brothers Nov 2002 B1
6482431 Smith Nov 2002 B2
6512023 Malofsky et al. Jan 2003 B1
D471984 Dunshee et al. Mar 2003 S
D472319 Oltmann Mar 2003 S
6559350 Tetreault et al. May 2003 B1
6579469 Nicholson et al. Jun 2003 B1
6582713 Newell et al. Jun 2003 B2
D477076 Wall Jul 2003 S
6589269 Zhu et al. Jul 2003 B2
6595940 D'Alessio et al. Jul 2003 B1
6596917 Oyaski Jul 2003 B2
6599318 Gabbay Jul 2003 B1
6620846 Jonn et al. Sep 2003 B1
D480879 Boehm et al. Oct 2003 S
6632450 Gregory Oct 2003 B1
6635272 Leaderman Oct 2003 B2
6652559 Tetreault et al. Nov 2003 B1
6667051 Gregory Dec 2003 B1
6712839 Lönne Mar 2004 B1
6787682 Gilman Sep 2004 B2
6837027 Hickey Jan 2005 B2
6841716 Tsutsumi Jan 2005 B1
6942683 Dunshee Sep 2005 B2
D515701 Horhota et al. Feb 2006 S
D516728 Wall Mar 2006 S
D520639 Dodd et al. May 2006 S
7041124 Purcell May 2006 B2
7044982 Milbocker May 2006 B2
7066934 Kirsch Jun 2006 B2
7122712 Lutri et al. Oct 2006 B2
7144390 Hannigan et al. Dec 2006 B1
7164054 Mori et al. Jan 2007 B2
D548348 Nash Aug 2007 S
7252837 Guo et al. Aug 2007 B2
D562461 Nash et al. Feb 2008 S
7371400 Borenstein et al. May 2008 B2
D574962 Atkins et al. Aug 2008 S
D580553 Nash Nov 2008 S
D581467 Winningham et al. Nov 2008 S
7457667 Skiba Nov 2008 B2
D582561 Sachi Dec 2008 S
D584415 Sachi Jan 2009 S
7576257 LaGreca, Sr. Aug 2009 B2
D611156 Dunshee Mar 2010 S
7713463 Reah et al. May 2010 B1
D618810 Tanigawa et al. Jun 2010 S
D621052 Kase Aug 2010 S
D621053 Kase Aug 2010 S
D624190 Neri Sep 2010 S
D632398 Bray et al. Feb 2011 S
D636881 Clemens et al. Apr 2011 S
7943811 Da Silva Macedo, Jr. May 2011 B2
7981136 Weiser Jul 2011 B2
7982087 Greener et al. Jul 2011 B2
D646789 Barth Oct 2011 S
8343606 Marchitto et al. Jan 2013 B2
8353966 Day et al. Jan 2013 B2
D676490 Bratter et al. Feb 2013 S
8372051 Scholz et al. Feb 2013 B2
D679098 Ogawa Apr 2013 S
D679402 Conrad-Vlasak et al. Apr 2013 S
D679403 Heinecke et al. Apr 2013 S
D679405 Arbesman Apr 2013 S
D679819 Peron Apr 2013 S
D679820 Peron Apr 2013 S
D685484 Brambilla Jul 2013 S
8528730 Grossman Sep 2013 B2
D691730 Smith et al. Oct 2013 S
D692566 Adoni Oct 2013 S
D693010 Mosa et al. Nov 2013 S
D694892 Chan et al. Dec 2013 S
8603053 Riesinger Dec 2013 B2
D697216 Chan et al. Jan 2014 S
8642831 Larsen et al. Feb 2014 B2
8663171 Tambourgi et al. Mar 2014 B2
D705429 Cheney et al. May 2014 S
D707829 Chan et al. Jun 2014 S
D708751 Chan et al. Jul 2014 S
8777986 Straehnz et al. Jul 2014 B2
D712045 Thornton Aug 2014 S
D713534 Manley, Jr. Sep 2014 S
D713967 Adoni Sep 2014 S
D714575 Mah Oct 2014 S
8884094 Lockwood et al. Nov 2014 B2
D718812 Sukhbaatar Dec 2014 S
9000251 Murphy et al. Apr 2015 B2
RE45510 Hisamitsu May 2015 E
D728803 Sinda et al. May 2015 S
D745688 Chan et al. Dec 2015 S
D745689 Chan et al. Dec 2015 S
D746479 Arefieg Dec 2015 S
RE45864 Peron Jan 2016 E
D746996 Karlsson et al. Jan 2016 S
D750789 Mackay et al. Mar 2016 S
D757950 Karlsson et al. May 2016 S
9339417 Ogawa May 2016 B2
9381284 Cornet et al. Jul 2016 B2
9440010 Locke Sep 2016 B2
9492171 Patenaude Nov 2016 B2
9623142 Jonn et al. Apr 2017 B2
D786350 Nakai et al. May 2017 S
D786351 Nakai et al. May 2017 S
D786352 Nakai et al. May 2017 S
D786353 Nakai et al. May 2017 S
D786972 Nakai et al. May 2017 S
9655622 Jonn et al. May 2017 B2
D790071 Ahsani Jun 2017 S
D824525 Lacy et al. Jul 2018 S
D833526 Nakai et al. Nov 2018 S
10434211 Jonn et al. Oct 2019 B2
10470935 Quintero Nov 2019 B2
20010002432 Bugge May 2001 A1
20010028943 Mashiko et al. Oct 2001 A1
20010037077 Wiemken Nov 2001 A1
20010051178 Blatchford Dec 2001 A1
20020018689 Badejo et al. Feb 2002 A1
20020019652 DaSilva et al. Feb 2002 A1
20020037310 Jonn et al. Mar 2002 A1
20020039867 Curro et al. Apr 2002 A1
20020049503 Milbocker Apr 2002 A1
20020185396 Mainwaring et al. Dec 2002 A1
20020192107 Hickey Dec 2002 A1
20020193721 Vandruff Dec 2002 A1
20030031499 Heard et al. Feb 2003 A1
20030050590 Kirsch Mar 2003 A1
20030093024 Falleiros et al. May 2003 A1
20030100955 Greenawalt et al. May 2003 A1
20030109819 Tsuruda et al. Jun 2003 A1
20030125654 Malik Jul 2003 A1
20030175824 Pishko et al. Sep 2003 A1
20030220596 Dunshee Nov 2003 A1
20030225355 Butler Dec 2003 A1
20040001879 Guo et al. Jan 2004 A1
20040060867 Kriksunov et al. Apr 2004 A1
20040106888 Lutri et al. Jun 2004 A1
20040120849 Stewart et al. Jun 2004 A1
20040142041 MacDonald et al. Jul 2004 A1
20040162512 Liedtke et al. Aug 2004 A1
20040220505 Worthley Nov 2004 A1
20050015036 Lutri et al. Jan 2005 A1
20050043820 Browning Feb 2005 A1
20050085757 Santanello Apr 2005 A1
20050147457 Badejo et al. Jul 2005 A1
20050153090 Marchitto et al. Jul 2005 A1
20050154340 Schlussel Jul 2005 A1
20050182443 Jonn et al. Aug 2005 A1
20050208100 Weber et al. Sep 2005 A1
20050288706 Widomski et al. Dec 2005 A1
20060009099 Jonn et al. Jan 2006 A1
20060058721 Lebner et al. Mar 2006 A1
20060141012 Gingras Jun 2006 A1
20060173394 Stroock et al. Aug 2006 A1
20060265005 Beese Nov 2006 A1
20070106195 Marcoux et al. May 2007 A1
20070218101 Johnson et al. Sep 2007 A1
20070272211 Kassner Nov 2007 A1
20070282238 Madsen et al. Dec 2007 A1
20070299542 Mathisen et al. Dec 2007 A1
20080051687 Rogers Feb 2008 A1
20080154168 Lutri Feb 2008 A1
20080086113 Tenney et al. Apr 2008 A1
20080109034 Mather et al. May 2008 A1
20080110961 Voegele et al. May 2008 A1
20080167633 Vannucci Jul 2008 A1
20080228219 Weiser Sep 2008 A1
20080228220 Weiser Sep 2008 A1
20080280037 Sheridan et al. Nov 2008 A1
20080302487 Goodman et al. Dec 2008 A1
20090074842 Hsu Mar 2009 A1
20100106120 Holm Apr 2010 A1
20100198161 Propp Aug 2010 A1
20100262091 Larsson Oct 2010 A1
20100298791 Jones et al. Nov 2010 A1
20110047766 McAulay et al. Mar 2011 A1
20110071415 Karwoski et al. Mar 2011 A1
20110092874 Baschnagel Apr 2011 A1
20110130699 Madsen et al. Jun 2011 A1
20110208102 Chawki Aug 2011 A1
20110253303 Miyachi et al. Oct 2011 A1
20120052230 Olsson et al. Mar 2012 A1
20120220912 Shang Aug 2012 A1
20120238933 Murphy et al. Sep 2012 A1
20120277645 Kikuta et al. Nov 2012 A1
20130012988 Blume et al. Jan 2013 A1
20130041337 Aali et al. Feb 2013 A1
20130066365 Belson et al. Mar 2013 A1
20130084323 Riebman et al. Apr 2013 A1
20130138068 Hu et al. May 2013 A1
20130143326 Tai et al. Jun 2013 A1
20130144399 Tai et al. Jun 2013 A1
20130204077 Nagale et al. Aug 2013 A1
20130218125 Stopek et al. Aug 2013 A1
20130245784 Tan et al. Sep 2013 A1
20130274717 Dunn Oct 2013 A1
20130282049 Peterson et al. Oct 2013 A1
20130317405 Ha et al. Nov 2013 A1
20140024989 Ueda Jan 2014 A1
20140107561 Dorian et al. Apr 2014 A1
20140121649 Calco May 2014 A1
20140155916 Hodgkinson et al. Jun 2014 A1
20140171888 Croizat et al. Jun 2014 A1
20140257348 Priewe et al. Sep 2014 A1
20140257517 Deichmann et al. Sep 2014 A1
20150057491 Goddard et al. Feb 2015 A1
20150209186 Abbott et al. Jul 2015 A1
20150257938 Pensier Sep 2015 A1
20150297413 Blanco Oct 2015 A1
20150314114 La Rosa Nov 2015 A1
20150351767 Zoll et al. Dec 2015 A1
20160030248 Potters Feb 2016 A1
20160089145 Quintero et al. Mar 2016 A1
20160199230 Doshi Jul 2016 A1
20160296673 Sambusseti Oct 2016 A1
20170035422 Belson Feb 2017 A1
20170056568 Shelton, IV et al. Mar 2017 A1
20170056569 Vendely et al. Mar 2017 A1
20170189159 Bartee et al. Jul 2017 A1
20170273837 Brueckner Sep 2017 A1
20170367806 Gingras et al. Dec 2017 A1
20180085103 Quintero et al. Mar 2018 A1
20180085259 Quintero Mar 2018 A1
20180085260 Quintero Mar 2018 A1
20190381207 Jonn et al. Dec 2019 A1
Foreign Referenced Citations (68)
Number Date Country
2005-215776 Sep 2005 AU
2262408 Aug 2000 CA
1697639 Nov 2005 CN
201441532 Apr 2010 CN
101965169 Feb 2011 CN
102755216 Oct 2012 CN
102781433 Nov 2012 CN
203234898 Oct 2013 CN
204766892 Nov 2015 CN
0532275 Mar 1993 EP
0730874 Sep 1996 EP
0746293 Dec 1996 EP
1161212 Aug 2000 EP
2359782 Aug 2011 EP
2377498 Oct 2011 EP
2731563 May 2014 EP
2531155 Oct 2014 EP
2805698 Nov 2014 EP
3574875 Dec 2019 EP
2078763 Jan 1982 GB
59-500046 Jan 1984 JP
61-203020 Dec 1986 JP
62-87624 Jun 1987 JP
01-265967 Oct 1988 JP
2-140948 Nov 1990 JP
3-56429 May 1991 JP
06-509966 Nov 1994 JP
7-016258 Jan 1995 JP
2001-265967 Sep 2001 JP
1130927 Nov 2001 JP
2002-512980 May 2002 JP
2002-521139 Jul 2002 JP
2002-537068 Nov 2002 JP
2003-052741 Feb 2003 JP
2003-153949 May 2003 JP
58-124123 Jan 2004 JP
2004-24905 Jan 2004 JP
2006-061263 Mar 2006 JP
2006-509966 Mar 2006 JP
2007-522882 Aug 2007 JP
3147394 Dec 2008 JP
2009-022730 Feb 2009 JP
1359502 May 2009 JP
2011-004850 Jan 2011 JP
1571238 Mar 2017 JP
1629290 Apr 2019 JP
241113 Oct 2006 MX
WO 1983002586 Aug 1983 WO
WO 1993004650 Mar 1993 WO
WO 1995004511 Feb 1995 WO
WO 1996040797 Dec 1996 WO
WO 1998026719 Jun 1998 WO
WO 2000006213 Feb 2000 WO
WO 2000049983 Aug 2000 WO
WO 2003008002 Jan 2003 WO
WO 2004049987 Jun 2004 WO
WO 2005007020 Jan 2005 WO
WO 2005051259 Jun 2005 WO
WO 2005079674 Sep 2005 WO
WO 2006017109 Feb 2006 WO
WO 2008082444 Jul 2008 WO
WO 2009067062 May 2009 WO
WO 2010134873 Nov 2010 WO
2011152368 Dec 2011 WO
WO 2013009725 Jan 2013 WO
WO 2014083570 Jun 2014 WO
WO 2014195710 Dec 2014 WO
WO 2015135351 Sep 2015 WO
Non-Patent Literature Citations (143)
Entry
U.S. Appl. No. 12/207,984, filed Sep. 10, 2008, US-2009-0076542-A1, U.S. Pat. No. 9,655,622, May 23, 2017, Grant, Jonn, et al.
U.S. Appl. No. 15/490,176, filed Apr. 18, 2017, US-2017-0216482, U.S. Pat. No. 10,434,211, Oct. 8, 2019, Grant, Jonn, et al.
U.S. Appl. No. 15/964,538, filed Apr. 27, 2018, US-2018-0243467, U.S. Pat. No. 10,398,802, Sep. 3, 2019, Grant, Jonn, et al.
U.S. Appl. No. 16/556,443, filed Aug. 30, 2019, US-2019-0381207, Publication, Jonn, et al.
U.S. Appl. No. 10/779,721, filed Feb. 18, 2004, US-2005-0182443-A1, Abandoned.
U.S. Appl. No. 16/556,471, filed Aug. 30, 2019, US-2019-0381206, Publication, Jonn, et al.
U.S. Appl. No. 12/163,021, filed Jun. 27, 2008, US-2008-0255610-A1, U.S. Pat. No. 9,623,142, Apr. 18, 2017, Grant, Jonn, et al.
U.S. Appl. No. 15/452,126, filed Mar. 7, 2017, US-2017-0173208, U.S. Pat. No. 10,398,800, Sep. 3, 2019, Grant, Jonn, et al.
U.S. Appl. No. 10/887,884, filed Jul. 12, 2004, US-2006-0009099-AI, Abandoned
U.S. Appl. No. 14/864,033, filed Sep. 24, 2015, US2016-0089145, Publication, Quintero, et al.
U.S. Appl. No. 16/387,634, filed Apr. 18, 2019, US-2019-0240074, Publication, Quintero, et al.
U.S. Appl. No. 29/635,782, filed Feb. 2, 2018, Filing, Quintero, et al.
U.S. Appl. No. 29/503,320, filed Sep. 25, 2014, U.S. Pat. No. D824,525, Jul. 31, 2018, Grant, Quintero, et al.
U.S. Appl. No. 29/648,487, filed May 22, 2018, U.S. Pat. No. D854,171, Jul. 16, 2019, Grant, Quintero, et al.
U.S. Appl. No. 29/690,950, filed May 13, 2019, Filing, Quintero, et al.
U.S. Appl. No. 15/675,159, filed Aug. 11, 2017, US-2018-0085260, U.S. Pat. No. 10,687,986, Jun. 23, 2020, Grant, Quintero, et al.
U.S. Appl. No. 16/907,930, filed Jun. 22, 2020, US-2020-0315858, Publication, Quintero, et al.
U.S. Appl. No. 29/613,662, filed Aug. 11, 2017, U.S. Pat. No. D848,624, May 14, 2019, Grant, Quintero, et al.
U.S. Appl. No. 29/683,074, filed Mar. 11, 2019, U.S. Pat. No. D907,217, Jan. 5, 2021, Grant, Quintero, et al.
U.S. Appl. No. 29/761,282, filed Dec. 8, 2020, Filing, Quintero, et al.
U.S. Appl. No. 15/280,303, filed Sep. 29, 2016, US-2018-0085259, U.S. Pat. No. 10,470,934, Nov. 12, 2019, Grant, Quintero, et al.
U.S. Appl. No. 16/598,249, filed Oct. 10, 2019, US-2020-0038253, Publication, Quintero, et al.
U.S. Appl. No. 15/467,537, filed Mar. 23, 2017, US-2018-0271712, U.S. Pat. No. 10,470,935, Nov. 12, 2019, Grant, Quintero, et al.
U.S. Appl. No. 17/143,883, filed Jan. 7, 2021, Filing, Quintero, et al.
U.S. Appl. No. 15/496,389, filed Apr. 25, 2017, US-2018-0303967, Publication, Quintero, et al.
U.S. Appl. No. 16/050,205, filed Jul. 31, 2018, US-2020-0038006, Publication, Quintero, et al.
JP 7040744, 1995, English claims.
JP 3059327, 1991, English claims.
Japanese Office Action dated Feb. 19, 2019 for Design Appln. No. 2018-017274.
Japanese Office Action dated Feb. 26, 2019 for Patent Appln. No. 515463.
3M™ Steri-Strip Adhesive Closures Product Catalog Brochure, (2011) 4 pages.
3M™ Steri-Strip Adhesive Closures Product Catalog Brochure, (2011) 8 pages.
3M™ Steri-Strip Adhesive Closures Product Catalog Brochure, (2012) 12 pages.
Allen, L.V. Jr et al Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems, 8th edition 2005 Lippincott Williams & Wilkins, Chapter 4, Dosage Form Design: Pharmaceutical and Formulation Considerations p. 131.
Ashley et al.: Further studies involving wound closure with a rapidly polymerizing adhesive; Plastic and Reconstructive Surgery; Apr. 1963; vol. 31; pp. 333-343.
Ashley et al.: Nonsutured closure of skin lacerations and nonsutured grafting of skin with a rapidly polymerizing adhesive; Qtrly Bull. Northwestern University (Evanston, III.) Medical School; 1962; vol. 36; pp. 189-194.
Brombeg et al.: Nonsuture fixation of split-thickness skin grafts; Surgery, Jun. 1964; vol. 55; pp. 846-853.
Cramer: Rapid Skin Grafting in Small Animals; Plastic and Reconstructive Surgery and the Transplantation Bull; Oct. 1962, vol. 30; pp. 149-150.
Cramer et al.: Autograft rejection induced by homografting. A phenomenon intermediate between homograft rejection and autoimmunity; Plastic and Reconstructive Surgery; Jun. 1965; vol. 35; pp. 572-587.
Demaria, E. ‘New skin closure system facilitates wound healing after cardiovascular implantable electronic device surgery’ World Journal of Clinical Cases (2015) 3(8) pp. 675-677.
Dermabond Prineo Skin Closure Systems (22 cm) Brochure (2014), 7 pages.
Dermabond Prineo Skin Closure Systems (22 cm) Brochure (2015), 2 pages.
Healthcare Packaging. Advanced Wound Care Products and packaging Needs. Jun. 5, 2017 (earliest online date), [site visited May 8, 2018]. Available from the Internet, URL:https://www.healthcarepackaging.com/article/applications/healthcare/advanced-wound-care-products-and-packaging-needs> (Year: 2017).
Inou: Studies on the Surgical Use of Plastic Adhesive; Am. Journal of Proctology; 1962; vol. 13; pp. 219-226.
Jesse et al.: Fixation of split-thickness skin grafts with adhesive; Plastic and Reconstructive Surgery; Mar. 1964; vol. 33; pp. 272-277.
Kaplan: A technique of nonsuture wound closure with a plastic tissue adhesive; Plastic and Reconstructive Surgery; Feb. 1966; vol. 37(2); pp. 139-142.
Keddie et al.: Intrafollicular tinea versicolor demonstrated on monomer plastic strips; Journal of Investigative Dermatology; Sep. 1963; vol. 41; pp. 103-106.
Lazar, H.L. et al. ‘Novel Adhesive Skin Closures Improve Wound Healing Following Saphenous Vein Harvesting’ J. Card Surg (2008) 23 pp. 152-155.
Leukosan SkinLink Application Guide (2006) 1 page.
Leukosan Skinlink. BSN Medical (2017) 1 page http://www.bsnmedical.com/products/wound%E2%80%90care%E2%80%90vascular/category%E2%80%90product%E2%80%90search/acute%E2%80%90wound%E2%80%90care/wound%E2%80%90closure/leukosanr%E2%80%90skinlink.html.
Pam Marketing Nut. Yikes! The Social Medica Quick Fix Band-Aids are Falling Off! Jul. 2012 [earliest online date], [site visited May 8, 2018]. Available from Internet, ,URL:http://www.pammarketingnut.com/2012/07/yikes-the-social-media-quick-fix-band-aids-are-falling-off/> (Year: 2012).
Parrish et al.: Synthetic resin adhesive for placement of skin grafts; American Surgeon; Nov. 1964; vol. 30; pp. 753-755.
Raekallio et al.: Acute reaction to arterial adhesive in healing skin wounds; Journal of Surgical Research; Mar. 1964; vol. 4; pp. 124-127.
Stone: Nonsuture closure of cutaneous lacerations, skin grafting and bowel anastomosis; American Surgeon; Mar. 1964; vol. 30; pp. 177-181.
TissuGlu Surgical Adhesive Patient Information Brochure. Cohera Medical, Inc. (2014) 6 pages.
TissuGlu FDA Summary of Safety and Effectiveness Data. Feb. 3, 2014 40 pages.
Topaz, M et al ‘The TopClosure 3S System, for skin stretching and a secure wound closure’ Eur J Plast Surg (2012) 35 pp. 533-543.
TopClosure 3S System—Skin Stretching and Secure Wound Closure System Product Information Sheet (2010) 15 pages.
Wang et al ‘Biodegradable microfluidic scaffolds for tissue engineering from amino alcohol-based poly(ester amide) elastomers’ Organogenesis (2010) 6:4, pp. 212-216.
Wolfe et al.: The application of hydrostatic pressure to the burn injury, an experimental study: Journal of Trauma: Injury Infections & critical Care; May 1962; vol. 2; pp. 262-272.
ZipLine medical Zip Surgical Skin Closure Brochure (2013) 4 pages.
Corrected International Search Report International Application No. PCT/US2005/004948 dated Jun. 22, 2005.
Extended European Search Report re: 14166813.7 dated Jul. 7, 2014.
International Preliminary Report on Patentability for International Application No. PCT/US2005/024042 dated Jan. 16, 2007.
International Search Report for International Application No. PCT/US2005/024042 dated May 12, 2006.
International Search Report for International Application No. PCT/US2005/004948 dated Jun. 9, 2009.
International Search Report re: PCT/US2015/051919 dated Apr. 14, 2016.
International Search Report re: PCT/US2017/052394 dated Nov. 21, 2017.
International Search Report re: PCT/US2017/052383 dated Dec. 6, 2017.
International Search Report re PCT/US2018/022842 dated Jun. 20, 2018.
International Search Report re PCT/US2018/022834 dated Jun. 22, 2018.
International Search Report re PCT/US2018/027790 dated Jun. 26, 2018.
Supplementary European Search Report for Application No. EP05769387 dated Jul. 9, 2009.
Supplementary European Search Report for Application No. EP05723162 dated Nov. 5, 2009.
Supplementary European Search Report for Application No. EP14166813 dated Jun. 30, 2014.
Written Opinion re: PCT/US2015/051919 dated Apr. 14, 2016.
Written Opinion re: PCT/US2017/052394 dated Nov. 21, 2017.
Written Opinion re: PCT/US2017/052383 dated Dec. 6, 2017.
Written Opinion re: PCT/US2018/022842 dated Jun. 20, 2018.
Written Opinion re: PCT/US2018/027790 dated Jun. 26, 2018.
Written Opinion re PCT/US2018/022834 dated Jun. 22, 2018.
Communication received from the USPTO for co-pending U.S. Appl. No. 10/887,884 dated Aug. 11, 2006.
Communication received from USPTO for co-pending U.S. Appl. No. 10/779,721 dated Mar. 28, 2007.
Communication received from USPTO for co-pending U.S. Appl. No. 10/779,721 dated Apr. 16, 2007.
Communication received from the USPTO for co-pending U.S. Appl. No. 10/887,884 dated Mar. 6, 2008.
Communication received from the USPTO for co-pending U.S. Appl. No. 10/887,884 dated Dec. 12, 2008.
Communication received from the USPTO for co-pending U.S. Appl. No. 12/207,984 dated May 11, 2011.
Communication received from the USPTO for co-pending U.S. Appl. No. 12/163,021 dated May 13, 2011.
Communication received from the USPTO for co-pending U.S. Appl. No. 12/163,021 dated Feb. 2, 2012.
Communication received from the USPTO for co-pending U.S. Appl. No. 12/163,021 dated Jun. 22, 2012.
Communication received from the USPTO for co-pending U.S. Appl. No. 12/207,984 dated Jun. 28, 2012.
Communication received from USPTO for co-pending U.S. Appl. No. 12/163,021 dated Jun. 22, 2012.
In re the U.S. Appl. No. 12/163,021 the Non-Final rejection dated Aug. 14, 2013.
In re the U.S. Appl. No. 12/163,021 the Final rejection dated Jan. 3, 2014.
In re the U.S. Appl. No. 12/207,984 the Non-Final rejection dated Aug. 22, 2013.
In re the U.S. Appl. No. 12/207,984 the Final rejection dated Dec. 4, 2013.
Office action received from USPTO for co-pending U.S. Appl. No. 10/887,884 dated Apr. 25, 2006.
Office action received from USPTO for co-pending U.S. Appl. No. 10/779,721 dated Aug. 21, 2006.
Office action received from USPTO for co-pending U.S. Appl. No. 10/887,884 dated Oct. 12, 2006.
Office action received from USPTO for co-pending U.S. Appl. No. 10/779,721 dated Jan. 9, 2007.
Office Communication received from USPTO for co-pending U.S. Appl. No. 10/887,884 dated Jan. 22, 2007.
Office Action received from USPTO for co-pending U.S. Appl. No. 10/887,884 dated Feb. 1, 2007.
Office Action received from the USPTO for co-pending U.S. Appl. No. 12/163,021.
Office action received from USPTO for co-pending U.S. Appl. No. 10/779,721 dated Jul. 27, 2007.
Office Action received from USPTO for co-pending U.S. Appl. No. 10/887,884 dated Oct. 16, 2007.
Office Action received from USPTO for co-pending U.S. Appl. No. 10/887,884 dated Mar. 6, 2008.
Office action received from USPTO for co-pending U.S. Appl. No. 10/779,721 dated May 19, 2008.
Office action received from USPTO for co-pending U.S. Appl. No. 12/163,021 dated Jan. 9, 2010.
Office action received from USPTO for co-pending U.S. Appl. No. 12/163,021 dated Sep. 1, 2010.
Office action received from USPTO for co-pending U.S. Appl. No. 12/207,984 dated Sep. 1, 2010.
Office action received from USPTO for co-pending U.S. Appl. No. 12/163,021 dated Dec. 9, 2010.
Office action received from USPTO for co-pending U.S. Appl. No. 12/207,984 dated Dec. 9, 2010.
Office action received from USPTO for co-pending U.S. Appl. No. 12/163,021 dated May 13, 2011.
Office action received from USPTO for co-pending U.S. Appl. No. 12/163,021 dated Jul. 18, 2011.
Office action received from USPTO for co-pending U.S. Appl. No. 12/207,984 dated Aug. 1, 2011.
Office action received from USPTO for co-pending U.S. Appl. No. 12/163,021 dated Jan. 10, 2012.
Office action received from USPTO for co-pending U.S. Appl. No. 12/207,984 dated Jan. 17, 2012.
Office action received from USPTO for co-pending U.S. Appl. No. 12/207,984 dated Apr. 26, 2012.
Office action received from USPTO for co-pending U.S. Appl. No. 12/163,021 dated May 1, 2012.
Office action received from USPTO for co-pending U.S. Appl. No. 12/163,021 dated Sep. 17, 2012.
Office action received from USPTO for co-pending U.S. Appl. No. 12/207,984 dated Sep. 25, 2012.
Office action received from USPTO for co-pending U.S. Appl. No. 12/163,021 dated Aug. 14, 2013.
Office action received from USPTO for co-pending U.S. Appl. No. 12/207,984 dated Aug. 22, 2013.
Office action received from USPTO for co-pending U.S. Appl. No. 12/207,984 dated Dec. 4, 2013.
Office action received from USPTO for co-pending U.S. Appl. No. 12/163,021 dated Jan. 3, 2014.
Office action received from USPTO for U.S. Appl. No. 15/964,538 dated Oct. 25, 2018.
Office action received from USPTO for U.S. Appl. No. 15/964,538 dated Dec. 27, 2018.
Office action received from USPTO for U.S. Appl. No. 15/490,176 dated Feb. 4, 2019.
Office action received from USPTO for U.S. Appl. No. 15/452,126 dated Nov. 16, 2018.
Office action received from USPTO for U.S. Appl. No. 14/864,033 dated Nov. 26, 2018.
Office action received from USPTO for U.S. Appl. No. 15/467,239 dated Feb. 28, 2019.
Office action received from USPTO for U.S. Appl. No. 15/278,376 dated Sep. 11, 2018.
Office action received from USPTO for U.S. Appl. No. 15/278,376 dated Feb. 21, 2019.
Office action received from USPTO for U.S. Appl. No. 15/675,159 dated May 14, 2019.
U.S. Appl. No. 09/430,177, filed Oct. 29, 1999.
U.S. Appl. No. 09/430,289, filed Oct. 29, 1999.
U.S. Appl. No. 09/430,180, filed Oct. 29, 1999.
U.S. Appl. No. 09/385,030, filed Aug. 30, 1999.
U.S. Appl. No. 09/176,889, filed Oct. 22, 1998.
U.S. Appl. No. 09/919,877, filed Aug. 2, 2001.
U.S. Appl. No. 10/779,721, filed Feb. 18, 2004.
N/A, “Scar nose & Rinoplasty Surgery—New Gel+Demo:Nose Silicone Gel Sheet (beige)www.newgelplus.com”, www.youtube.com, 2012, pp. 1-3, Page Number.
N/A, “Silagen Silicone Sheeting Strips Review|the skin spot”, www.youtube.com, 2017, pp. 1-3, Page Number.
Related Publications (1)
Number Date Country
20200038253 A1 Feb 2020 US
Continuations (1)
Number Date Country
Parent 15467537 Mar 2017 US
Child 16598249 US